Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Rilvegostomig
D702KC00001
Phase 2 small_molecule active
Quick answer
Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Rilvegostomig for metastatic non-small cell lung cancer (NSCLC) is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- metastatic non-small cell lung cancer (NSCLC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active